Edit

Deciphera Pharma

http://www.deciphera.com/

Last activity: 11.06.2024

Active

Categories: DrugFamilyInformationLivingMedtechPlatformProduct

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Australia, Canada, Hong Kong, and China. For more information, visit www.deciphera.com.

Likes

191

Followers

727

Followers

16.44K

Website visits

11K /mo.

Mentions

Location: United States, Massachusetts, Waltham

Employees: 201-500

Phone: +1 781-209-6400

Total raised: $127M

Founded date: 2003

Twitter

Facebook

Investors 2

Date	Name	Website
-	SV Health ...	svhealthin...
-	New Leaf V...	nlvpartner...

Funding Rounds 2

Date	Series	Amount	Investors
14.06.2017	Series C	$52M	-
21.09.2015	Series B	$75M	-

Mentions in press and media 25

Date	Title	Description
11.06.2024	Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)	OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April ...
17.09.2021	Deciphera Pharmaceuticals : Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor (Form 8-K)	Deciphera Announces Positive CHMP Opinion for QINLOCK®for the Treatment of Fourth-line Gastrointestinal Stromal Tumor - European Commission Decision Anticipated by the Fourth Quarter of 2021 - Waltham, MA - September 17, 2021 - Deciphera Ph...
23.11.2020	The Boston Globe Names Deciphera a Top Place to Work for 2020	WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, has been named one of the Top Places t...
22.06.2020	Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor	June 22, 2020 at 7:00 AM EDTPDF Version
08.06.2020	Deciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet Oncology	June 8, 2020 at 7:30 AM EDTPDF Version
29.05.2020	Deciphera Pharmaceuticals Announces Presentations of Positive Patient Reported Outcomes Results from INVICTUS Phase 3 Study of QINLOCKTM (ripretinib) in Patients with Fourth-Line Advanced GIST at the ...	Patients Receiving QINLOCK for Fourth-line GIST Reported Improved Quality of Life and Better Physical and Role Functioning Compared with a Decline in Placebo-
16.12.2019	Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors	– Application is Being Reviewed Under FDA’s Real-Time Oncology Review (RTOR) Pilot Program –
28.10.2019	FDA to split Blueprint’s cancer drug application in two	Shares of Blueprint were down about 5 percent on the NASDAQ Monday morning following the news. GIST is a sarcoma, meaning a cancer of the connective tissue. Avapritinib is an inhibitor of KIT and PDGFRa that is also in development for advan...
28.09.2017	Term Sheet — Thursday, September 28	DIAL UP THE DRAMA Good morning, Term Sheet readers! Paid Content You can't secure what you can't see From ExtraHop BITCOIN SOUND OFF: The Wolf of Wall Street has spoken. Jordan Belfort, the former stockbroker who pled guilty to fraud, calle...
19.09.2017	Term Sheet — Tuesday, September 19	VCs VERSUS ICOs Companies have raised more than $1.7 billion through initial coin offerings this year, surpassing early-stage VC funding for Internet companies. It’s easy to see why an ICO is appealing to tech founders (No due diligence! LO...
05.09.2017	Term Sheet — Tuesday, September 5	CATCH UP Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop SQUEEZED OUT: On Friday, we bid farewell to Juicero, our favorite juicer company to make fun of on Twitter. After raising...
10.07.2017	Chemotherapy before breast cancer surgery might fuel metastasis	When breast cancer patients get chemotherapy before surgery to remove their tumor, it can make remaining malignant cells spread to distant sites, resulting in incurable metastatic cancer, scientists reported last week. The main goal of pre-...
01.06.2017	Deciphera Pharmaceuticals Raises $52M in Series C Financing	Deciphera Pharmaceuticals, a Waltham, MA-based clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, closed a $52m Series C financing. The round was led by Viking Global Investors LP, Redmil...
01.06.2017	Deciphera Pharmaceuticals Raises $52 Million Series C	WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it closed a $52 million Series C financing led by Vik...
01.06.2017	Deciphera Pharmaceuticals Snags $52M	WALTHAM, MA, Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it closed a $52 million Series C. >> Click here for more funding...
03.11.2016	The top 15 healthcare deals of 2016	There has been $13.1 billion invested across 1,287 deals so far this year Even as venture funding has slowed down this year, healthcare has remained one of the top spaces for companies to raise money. In the first quarter of this year, even...
06.01.2016	Deciphera Pharmaceuticals Increases Size of Series B Round to over $90M	Deciphera Pharmaceuticals, a Waltham, MA-based clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments, has increased the size of its Series B financing to over $90m. SV Life Sciences made the additio...
05.01.2016	Daily funding roundup - January 5, 2016	PAG raised $3.6B; Deciphera Pharmaceuticals raised $90M; Millendo Therapeutics Inc secured $62M Snapcart, an Indonesia-based cashback app, has raised $1.675 million in "pre-series A funding". Investors in this round include SPH Me...
21.09.2015	Deciphera raises $75M directed toward kinase-inhibiting cancer drug	Taylor aims to eventually put together a broad syndicate of crossover investors that can support an IPO, but the $75 million, which should fund Deciphera through 2017, gives the company some time to decide when. It’ll gather clinical data o...
21.09.2015	Daily funding roundup - September 21, 2015	Deciphera bagged $75M; Portea raised $37.5M; Just Biotherapeutics secured $15M BidFlyer, an Israeli startup that is a white-label platform for airlines, has raised $1 million in funding for its business model, which involves putting small b...
21.09.2015	Kinase-focused Deciphera gets marquee backing for a big $75M venture round	A little more than a year after Deciphera CEO Mike Taylor set up an office for the biotech in the Boston area, the cancer drug developer has rounded up a whopping $75 million B round to make a clinical push for its top cancer drug candidate...
21.09.2015	Deciphera Pharmaceuticals Nets $75M Series B	WALTHAM, MA, Clinical-stage biotechnology company has closed a $75 million Series B financing. >> Click here for more funding data on Deciphera Pharmaceuticals >> To export Deciphera Pharmaceuticals funding data to PDF and E...
21.09.2015	Deciphera Pharmaceuticals Closes $75M Series B Financing	Deciphera Pharmaceuticals, a Waltham, MA-based clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, closed a $75m Series B financing. The ro...
-	FDA to split Blueprint’s cancer drug application in two	The Food and Drug Administration will review a biotech company’s approval application for a cancer drug in two parts. Cambridge, Massachusetts-based Blueprint Medicines said Monday that the FDA would split its application for the drug avapr...
-	Deciphera raises $75M directed toward kinase-inhibiting cancer drug	Waltham, Massachusetts-based Deciphera has now raised $75 million with funding led by New Leaf Ventures, which was joined by the company’s lone major longtime backer, an unnamed “high net worth” investor, according to Xconomy. The funding w...

Deciphera Pharma

Investors 2

Funding Rounds 2

Mentions in press and media 25

Reviews 0